Omerio-D Capsule is a combination pharmaceutical formulation containing Domperidone 10 mg and Omeprazole 20 mg, designed to manage gastrointestinal disorders involving acid reflux and motility disturbances. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and increasing lower esophageal sphincter pressure, thereby alleviating symptoms such as nausea, vomiting, and bloating. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of Domperidone and Omeprazole in Omerio-D Capsule offers comprehensive management of upper gastrointestinal symptoms by reducing acid production and improving gastric motility. This combination is particularly beneficial for patients with delayed gastric emptying and acid reflux symptoms. Omerio-D Capsule should be administered as prescribed by a healthcare professional, with consideration of patient-specific factors such as medical history and concomitant medications. Caution is advised in patients with cardiac conditions due to Domperidone’s potential to prolong the QT interval. Regular monitoring and adherence to recommended dosage enhance therapeutic outcomes and minimize adverse effects.